$DSS Great...what a undervalued company.... DSS announced the closing of its acquisition of Impact BioMedical on August 21, 2020. Impact BioMedical’s ownership of a suite of antiviral and medical technologies has been valued at $382 million by Destum Partners, known globally for its high level of expertise and capability in independently valuing and advising on pharmaceutical technology. impbio.com
3
3